ERAS NASDAQ
Erasca, Inc.
1W: +3.4%
1M: -10.0%
3M: -21.8%
YTD: +310.6%
1Y: +567.0%
3Y: +579.3%
5Y: -23.4%
$14.74
+0.16 (+1.10%)
Weekly Expected Move ±7.5%
$13
$14
$15
$16
$17
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09
These ten healthcare stocks posted the biggest one-month losses
Stock Traders Purchase Large Volume of Erasca Call Options (NASDAQ:ERAS)
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
10 mid-cap healthcare stocks with the strongest momentum grades
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Engineers Gate Manager LP Takes Position in Erasca, Inc. $ERAS
Frazier Life Sciences Management L.P. Has $457.55 Million Stock Position in Erasca, Inc. $ERAS
AXQ Capital LP Acquires Shares of 63,443 Erasca, Inc. $ERAS
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
BlackRock Inc. Takes $387.54 Million Position in Erasca, Inc. $ERAS
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB
Bank of America Corp DE Raises Position in Erasca, Inc. $ERAS
Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS
ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit – Investors with Losses Encouraged to Contact Hagens Berman
The Gross Law Firm Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS
Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); Commvault Systems, Inc. (NASDAQ: CVLT); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your Behalf
Erasca prices upsized $550M public offering of common stock at $17.50 per share
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BitGo Holdings, Inc. (BTGO), ADMA Biologics, Inc. (ADMA), and Erasca, Inc. (ERAS) Announced by Holzer & Holzer, LLC
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Erasca (ERAS) director receives grant of 29,888 stock options at $16.01 - Stock Titan
[Form 4] Erasca, Inc. Insider Trading Activity - Stock Titan
Erasca (ERAS) director receives 29,888-share stock option grant at $16.01 - Stock Titan
Erasca (ERAS) director Alexander Casdin awarded 29,888 stock options at $16.01 strike - Stock Titan
Erasca (NASDAQ: ERAS) director receives stock options for 29,888 shares - Stock Titan
Erasca (NASDAQ: ERAS) director receives 29,888 stock options vesting in 2027 - Stock Titan
Erasca, Inc.(NasdaqGS: ERAS) added to Russell 2500 Growth Benchmark - marketscreener.com
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS - Morningstar
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS - GlobeNewswire
Erasca, Inc.(NasdaqGS: ERAS) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Erasca, Inc.(NasdaqGS: ERAS) added to Russell 2000 Growth Benchmark - marketscreener.com
ERASCA CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
Erasca, Inc. Actuals & Estimates (NASDAQ:ERAS) - TradingView
Erasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk - simplywall.st
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Erasca, Inc. - GlobeNewswire
ERASCA, INC. (ERAS) INVESTOR ALERT Investors With Large - GlobeNewswire
Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
ERAS Deadline Alert: Levi & Korsinsky Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS
DEADLINE ALERT for BTGO, ERAS, NNOX, and MSFT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
(NASDAQ:ERAS) ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against ADMA Biologics, Inc. (ADMA), Erasca, Inc. (ERAS), and Nano-X Imaging Ltd. (NNOX) Announced by Holzer & Holzer, LLC
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ERAS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm
Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials
SHAREHOLDER ALERT: Erasca, Inc. Sued For Securities Fraud by Block & Leviton LLP; August 10 Deadline To Seek To Serve As Lead Plaintiff
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations
Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says
Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20 - Yahoo Finance
Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. (NASDAQ:ERAS) on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Erasca to Present at the Jefferies Global Healthcare Conference
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Erasca Reports First Quarter 2026 Business Updates and Financial Results
ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm
Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation
Revolution Medicines wins FDA nod to provide early access to cancer therapy
Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results
ERAS stock slumps against RVMD rally — analyst stays bullish - MSN
Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges
Why Erasca Stock Is Tumbling Despite Drug Hopes - TipRanks
Erasca stock sinks 50% after patient death in drug trial
Patient Death Drags Erasca (ERAS) Shares by 48%
Patient Death Drags Erasca (ERAS) Shares by 48% - Yahoo Finance
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's
Erasca (NASDAQ: ERAS) details 2026 virtual meeting and executive pay - Stock Titan
Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its Value
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 - Slideshow (NASDAQ:ERAS) 2026-04-28 - Seeking Alpha
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data
Erasca (ERAS) Stock Crashes 50% After Patient Death in Cancer Drug Trial - CoinCentral
12 Health Care Stocks Moving In Tuesday's Intraday Session
Crude Oil Gains Over 3%; General Motors Earnings Top Views
Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Erasca, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors to Contact the Firm to Possibly Recover Losses